The incidence of venous thromboembolism (VTE) is more than 1‰ annually in the general
population and increases further in cancer patients. The risk of VTE is higher in multiple …

The ubiquitin proteasome pathway was discovered in the 1980s to be a central component
of the cellular protein-degradation machinery with essential functions in homeostasis, which …

The transcription factor nuclear factor (NF)-κB is activated in certain cancers and in response
to chemotherapy and radiation. The transcriptional activation of genes associated with cell …

Background Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has
been shown in preclinical and phase 1 studies to have antimyeloma activity. Methods In this …

Purpose The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and
reliable tool is needed to stratify patients with MM. We combined the International Staging …

Background Daratumumab showed promising efficacy alone and with lenalidomide and
dexamethasone in a phase 1–2 study involving patients with relapsed or refractory multiple …

Background Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling
lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with …

Background In patients with newly diagnosed multiple myeloma, the effect of adding
autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and …

PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and
pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-…

Background New treatment options are needed for patients with multiple myeloma that is
refractory to proteasome inhibitors and immunomodulatory drugs. We assessed daratumumab, …